297 related articles for article (PubMed ID: 15020269)
1. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
3. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
6. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
7. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
[TBL] [Abstract][Full Text] [Related]
8. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
10. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
13. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
[TBL] [Abstract][Full Text] [Related]
14. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
[TBL] [Abstract][Full Text] [Related]
17. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Krykowski E; Warzocha K; Robak T
Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
19. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
